What happens to brain outside the thermal ablation zones? An assessment of needle-based therapeutic ultrasound in survival swineINTERNATIONAL JOURNAL OF HYPERTHERMIAIF32022-09-262OAAI
Pilot study on the effects of low intensity focused ultrasound in a swine model of neuropathic painJOURNAL OF NEUROSURGERYIF3.62021-11-0120OA
Late adolescence mortality in mice with brain-specific deletion of the volume-regulated anion channel subunit LRRC8AFASEB JOURNALIF4.22021-09-0111OA
Predicting ablation zones with multislice volumetric 2-D magnetic resonance thermal imaging用多层体积二维磁共振热成像预测消融区INTERNATIONAL JOURNAL OF HYPERTHERMIAIF32021-06-217OAAI
The neuroprotective properties of the superoxide dismutase mimetic tempol correlate with its ability to reduce pathological glutamate release in a rodent model of strokeFREE RADICAL BIOLOGY AND MEDICINEIF8.22014-12-0153OAAI
Deficits in neuronal cytochrome P450 activity attenuate opioid analgesia but not opioid side effectsEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72014-10-0110OAAI
Antinociceptive activity of CC44, a biotinylated improgan congenerEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72013-08-014OAAI
Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesicPAINIF5.52011-04-0115OAAI
Inhibition of brain [3H]cimetidine binding by improgan-like antinociceptive drugsEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72010-04-012OAAI
Significance of cannabinoid CB1 receptors in improgan antinociceptionJOURNAL OF PAINIF42007-11-0114OAAI
Cannabinoid-improgan cross-tolerance:: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptorEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72006-11-0110PREAI
Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesicEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72005-10-018PREAI
Activation of spinal histamine H3 receptors inhibits mechanical nociceptionEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72003-06-0152PREAI
Inhibition of improgan antinociception by the cannabinoid (CB)1 antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-( 2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A):: Llack of obligatory role for endocannabinoids acting at CB1 receptorsJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82002-01-0130PREAI
Significance of GABAergic systems in the action of improgan, a non-opioid analgesicLIFE SCIENCESIF5.12001-05-0129PREAI
Antinociceptive activity of derivatives of improgran and burimamidePHARMACOLOGY BIOCHEMISTRY AND BEHAVIORIF2.52000-01-0115PRE
Antinociceptive activity of impentamine, a histamine congener, after CNS administrationLIFE SCIENCESIF5.11998-12-0112PREAI
MODULATION OF MORPHINE ANTINOCICEPTION BY THE BRAIN-PENETRATING H-2 ANTAGONIST ZOLANTIDINE - DETAILED CHARACTERIZATION IN 5 NOCICEPTIVE TEST SYSTEMSPHARMACOLOGY BIOCHEMISTRY AND BEHAVIORIF2.51995-03-0119PRE
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向